@prefix nkg: <https://w3id.org/um/neurodkg/> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix this: <http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM> .
@prefix sub: <http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0008114> a bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/MONDO_0008114>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/DRUGBANK:DB01175>;
    a rdf:Statement;
    rdfs:label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62].";
    bl:has_population_context sub:context;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:publications <https://pubmed.ncbi.nlm.nih.gov/30101713>;
    bl:relation nkg:OffLabelIndication .
  
  sub:context a bl:Cohort;
    rdfs:label "adults" .
  
  <https://identifiers.org/DRUGBANK:DB01175> a bl:Drug .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2021-08-25T14:52:33.344024"^^xsd:dateTime .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
    npx:hasSignature "ZhTHDwytjnomCNC0hmlbG+CJfBrD7z/xB70O6L0Rn+y7MK9gjicCRkdI3xpYiud7kWlvm4UHyvpn9dsgkarP/7Y0fC23KOQw5gPsRvvruPEeKojbMtMJfRvst7jbe4FTmoO+U002ZFOkNkL0odAoFPcMAhTnGvoIyOThakDUbow=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2021-08-25T14:52:33.344024"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-7641-6446;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}